



## Anti-SARS-CoV-2/COVID-19 Drugs and Vaccines

Guest Editors:

**Prof. Dr. Vasso Apostolopoulos**

Institute for Health and Sport,  
Victoria University, Melbourne,  
VIC 3011, Australia

Vasso.Apostolopoulos@  
vu.edu.au

**Dr. Majid**

**Hassanzadeganroudsari**

Institute of Health and Sports,  
Victoria University, Melbourne,  
VIC 3011, Australia

Majid.Hassanzadeganroudsari@  
vu.edu.au

Deadline for manuscript  
submissions:

**31 December 2021**

### Message from the Guest Editors

Dear Colleagues,

A novel strain of coronavirus, SARS-CoV-2, the causative agent of coronavirus disease (COVID-19) was first identified in late 2019 and triggered a pandemic which has been ongoing since March 2020. The development of effective therapeutics is an urgent global priority to stop the spread of COVID-19 infections and prevent further fatalities. As such, a number of platforms such as drugs, vaccines, monoclonal antibodies, pharmacological therapy, plasma therapy, immune boosters, and alternative medicines have been explored.

In this Special Issue of *Biologics*, the focus will be on the development of vaccines, pharmacological therapy, alternative medicines, monoclonal antibodies, plasma therapy, preclinical studies, clinical trials, replication, viral life cycle, and pathogenesis of SARS-CoV-2, as well as areas of identification of novel drug targets and any form of treatment models against COVID-19 infection. In vitro, in vivo, in silico, preclinical, and clinical trials are all welcome.

This Special Issue is for reviews or original research papers on biologics against the SARS-CoV-2 virus/COVID-19.

